Breast (Edinburgh, Scotland)

· 7 papers in corpus
observational 2025
doi:10.1016/j.breast.2025.104505 ·PMID:40403485

Hereditary breast and ovarian cancer (HBOC) is one of the most frequent genetic cancer predisposition syndromes. Individuals at risk are identified mainly by family history and histopathological criteria. The current standard genetic testin…

2023
observational 2021
doi:10.1016/j.breast.2021.07.010 ·PMID:34304065

BACKGROUND: Some studies suggested a decreased ovarian reserve among BRCA1/2 pathogenic variant carriers, with conflicting results. METHODS: We conducted a retrospective single-center observational study of ovarian reserve and spontaneous …

other 2021
doi:10.1016/j.breast.2021.10.011 ·PMID:34736091

BACKGROUND: Because a number of years may be required for normal cells to develop into carcinoma, genes involved in tumorigenesis and progression might differ among breast cancers in young women and those in older women. The present study s…

meta-analysis 2021
doi:10.1016/j.breast.2021.09.006 ·PMID:34627117

INTRODUCTION: Preliminary clinical evidence suggests a detrimental effect of pathogenic variants of BRCA1 and 2 genes on fertility outcome. This meta-analysis evaluates whether women carrying BRCA mutations (BRCAm) have decreased ovarian re…

lab-animal 2017
doi:10.1016/j.breast.2017.06.007 ·PMID:28649033

Fibrocystic Breast Disease (FBD) or Fibrocystic change (FC) affects about 60% of women at some time during their life. Although usually benign, it is often associated with pain and tenderness (mastalgia). The synthetic steroid danazol has b…

meta-analysis 2007
doi:10.1016/j.breast.2007.03.003 ·PMID:17509880

Several agents have been utilised for therapy of mastalgia based on data from small trials. No meta-analysis of trials on mastalgia exists. We have conducted a meta-analysis on trials on mastalgia published in the English language. Study wa…